An 111In-labeled anti-PSMA monoclonal antibody (mAb), 111In-capromab pendetide (ProstaScint), is the first US-FDA-approved radiopharmaceutical agent for the detection of prostate cancer via gamma scintigraphy or single photon-emission computed tomography (SPECT) [16]. This evidence concerns the gene FOLH1 and prostate carcinoma.